This trial is evaluating whether MOR00208 will improve 1 primary outcome and 15 secondary outcomes in patients with Stage IV Small Lymphocytic Lymphoma. Measurement will happen over the course of Baseline.
This trial requires 41 total participants across 2 different treatment groups
This trial involves 2 different treatments. MOR00208 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"The signs of prolymphocytic leukemia are similar to B-cell lymphoblastic lymphoma, but prolymphocytic leukemia can often progress to B-cell lymphosarcoma. Prolymphocytic leukemia should be distinguished from lymphoid malignancy." - Anonymous Online Contributor
"Leukemia, prolymphocytic and B-CLL cannot be cured. However, some patients can have remission for decades; long-term remission is rarely obtained. Long-term survival varies because many patients have late disease recurrences that can be fatal." - Anonymous Online Contributor
"Leukemia and prolymphocytic illness, especially acute myelogenous leukemia, are diseases that can cause sudden bleeding and bruising as an indicator of high leukocyte count. These illnesses also affect one's body immunity." - Anonymous Online Contributor
"Leukemia and prolymphocytic diseases occur when hematopoietic cells fail to mature and behave normally. These diseases are characterized by the accumulation of leukemic cells and prolymphocytic cells in the lymphatic system, bone marrow, and other sites. The underlying causes of leukemia and prolymphocytic diseases vary, but generally involve a combination of genetic, immunologic, environmental, and possibly occupational influences." - Anonymous Online Contributor
"1.7 million people will develop leukemia in the U.S. over the next year. In the first instance, leukemia will be more common among African Americans, but by the end of the first year, they will comprise the majority of reported cases." - Anonymous Online Contributor
"The therapeutic approach is basically that of chronic myelogenous leukemia (CML) and chronic lymphocytic leukemia (CLL). Both have been cured of myelosis or lymphocytosis by standard chemotherapy, particularly by chemotherapy regimens containing anthracycline, a purine analogue, or a nitrogen mustard drug. In addition, CLL and CML both respond well to newer targeted therapy. Prognosis in both CML and CLL is variable. In some patients, the disease progresses rapidly; in others, the disease is extremely long-lasting. The survival of patients with chronic myelogenous leukemia is estimated to be 7.0 to 10.0 years from diagnosis." - Anonymous Online Contributor
"Our group has continued to study various aspects of leukemia such as [drug resistance, development of secondary tumors, and other factors involved in leukemia development and pathogenesis(https://clinicaltrials.gov/ct2/show/NCT00236939?term = leukemia&term2 = prolymphocytic). Furthermore, [power] offers easy ways to search recent trials for leukemias and their treatment by condition, treatment, or location." - Anonymous Online Contributor
"There is good evidence that therapy with azacitidine in high-risk myelodysplastic syndrome and in chronic myelogenous leukemia has improved survival over last decade. There is low quality evidence that alemtuzumab, in combination with dasatinib, may improve the survival of newly diagnosed patients with myelodysplastic syndrome progressing from myelodysplastic syndromes, while there is no evidence it improves survival in chronic myelogenous leukemia patients with blast crisis." - Anonymous Online Contributor
"Overall survival of prolymphocytic leukemia is about 60%. However, it is slightly higher than that of leukemia without prolymphocytic features. It is important to get a detailed understanding of the features of leukemia when diagnosing; because there are few known features which can increase the life expectancy of patients suffering from prolymphocytic leukemia." - Anonymous Online Contributor
"(i) Data from a recent study here reported, although not directly compared to other agents, suggests the interest of such clinical evaluation of mor00208. (ii) Clinically insignificant side effects were noted in our study and were typical of other therapeutic trials. (iii) Mor00208 is a promising new agent, with potential clinical impact that deserves clinical evaluation." - Anonymous Online Contributor
"In this review, the authors discuss the value of clinical trials for all subtypes of leukemia and all stages of prolymphocytic leukemia, and provide guidelines on which type of patients to consider clinical trial involvement and in which trials to consider for which patients. They illustrate these by discussing the benefit and risks of clinical trials using the FDA investigational new drug (IND) pathway in patients with chronic lymphocytic leukemia ( CLL ) who do not have a mutated IGHV, one of the genetic mutations that is found in most patients with CLL, are in the relapsing or the early stages of follicular lymphoma ( FL ), and are in the relapsing phase in chronic lymphocytic leukemia (CLL)." - Anonymous Online Contributor
"Leukemias can have unpredictable and deadly effects on patients with or without treatment. Leukemia can be diagnosed either in children or adults. There is no doubt about leukemia being deadly and the way it reacts to treatment can be unpredictable. There are many factors, such as treatments chosen, the time of diagnosis, as well as the stage and progression of the disease that affect a patient’s survival. There are many types of Leukemia. You could be diagnosed with acute myeloid leukemia, acute lymphoblastic leukemia or chronic myeloid leukemia." - Anonymous Online Contributor